Exploring the Prognosis of Breast Cancer with Synchronous Distant Nonregional Lymph Node Metastasis and Establishing a Predictive Model: A Population-Based Study

Hong Lin, Jianxiong Lin, Yanxuan Wu, Guoxi Liang, Jiating Sun, and Liming Chen

1Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
2Department of Hematology and Oncology, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
3Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
4Department of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China

Correspondence should be addressed to Liming Chen; angelchen09@163.com

Hong Lin and Jianxiong Lin contributed equally to this work.

Received 14 July 2021; Revised 1 November 2021; Accepted 22 November 2021; Published 12 January 2022

Copyright © 2022 Hong Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. We aimed to explore the prognosis of breast cancer patients with synchronous isolated distant lymph node metastasis (SDLNM). Methods. We extracted information from the Surveillance, Epidemiology, and End Results Program. Kaplan-Meier and Cox regression analyses were used to compare overall survival (OS). Fine-Gray test was utilized to compare breast cancer-specific survival (BCSS). We applied propensity score matching (PSM) to balance confounders. In total, 692 SDLNM patients were allocated into training and validation cohorts. Univariate and multivariate analyses were implemented to determine independent prognostic variables. A nomogram predicting OS of SDLNM patients was constructed. Calibration curves and receiver operating characteristic curves were utilized to access the predictive model. Results. Cox regression and PSM analysis showed that the prognosis of SDLNM patients was similar to breast cancer patients in stage TnN3cM0 and superior to patients with other oligometastasis (SDLNM vs. TnN3cM0, \( p = 0.778 \); SDLNM vs. other oligometastasis: HR 0.767, 95% CI, 0.672-0.875, \( p < 0.001 \)). A nomogram was established to predict 1-, 3-, and 5-year OS for SDLNM patients. All C-indexes and AUCs were greater than 0.7. Calibration curves implied accurate prediction. For patients receiving mastectomy, postoperative chemotherapy and radiotherapy were significant. Conclusions. Breast cancer with SDLNM has a similar OS and BCSS with locally advanced disease. Comprehensive treatment was associated with better prognosis compared with palliative therapy. We constructed a predictive model for SDLNM breast cancer. It will be necessary to design large-scale prospective trials to confirm our results and validate the predictive model.

1. Introduction

Breast cancer is the most common cancer among women. There were approximately 2 million new breast cancers worldwide in 2017, of which 1.9 million were women [1]. Approximately 5-8% of breast neoplasms are initially diagnosed as metastatic breast cancers (MBCs), which have a poor prognosis and are mainly treated with palliative therapy [2, 3]. Currently, according to the 8th Edition AJCC Cancer Staging, breast cancer with isolated distant lymph node metastasis belongs to MBC [4]. Regional lymph nodes of the breast include the ipsilateral axillary lymph node, ipsilateral internal lymph node, ipsilateral supraclavicular lymph node, which are defined by the National Comprehensive Cancer Network [5]. Distant lymph nodes, including cervical, contralateral axillary, contralateral
supraclavicular, and contralateral internal mammary lymph nodes, are nonregional lymph nodes. Staging and treatment for breast cancer patients with isolated distant lymph node metastasis still remain controversial. In fact, lymphatic drainage of the breast is dominated by axillary drainage, but external axillary drainage can also be found in 20–27% of cases, which includes the ipsilateral internal mammary chain (17%), intramammary (3%), interpectoral (2%), and supraclavicular (2%) nodes [6]. Contralateral axillary lymph node drainage is rare, only 0–2%, while reverse drainage of cervical nodes is even more infrequent [7, 8]. In general, damage to the ipsilateral lymphatic network increases the probability of abnormal drainage [7, 9–11]. Distant nonregional lymph node metastasis (DLNM) includes simultaneous and synchronous metastasis. The former indicates that metastasis existed at the initial diagnosis of breast cancer, and the latter indicates that DLNM took the form of recurrence after treatment. The two modalities are similar in proportion [12].

Supraclavicular lymph node metastasis (SLNM) is used to be considered as stage IV disease. However, Brito et al. [13] demonstrated that the survival outcome of SLNM after combined therapy was similar to that of stage IIIb and was significantly superior to those with visceral metastasis. Thus, the American Joint Committee on Cancer (AJCC) staging system classified SLNM as stage III in 2002 [14]. Indeed, supraclavicular nodes belong to deep cervical nodes. Since tumor cells migrate to distant lymph nodes through lymph rather than blood, some investigators believe that DLNM should also not be classified as stage M1 [9, 11, 15–19]. Several studies propose that treatment for locally advanced breast cancer significantly improves the prognosis of DLNM patients [9, 10, 16–18, 20–22]. However, Guru et al. [23] considered that the prognosis of DLNM patients is similar to that of breast cancer patients with oligometastasis.

In order to address this controversial phenomenon, we conducted a study to compare the prognosis of synchronous isolated distant lymph node metastasis (SDLNM) with that of stage TnN3cM0 and other oligometastasis, as well as explore the role of multidisciplinary therapy for SDLNM patients. Moreover, we developed a predictive model to assess the prognosis of SDLNM patients. A nomogram is an alternative prognostic reference tool. It integrates complex demographic and clinico-pathological features and translates them into visualized mathematical statistical model to achieve individualized prognostic prediction [24–26].

2. Materials and Methods

2.1. Material Acquisition. We retrieved materials from the Surveillance, Epidemiology, and End Results (SEER) program. The enrolled patients were required to meet the following criteria: (1) initially diagnosed with breast cancer, (2) were in stage TnN3cM0, or in stage IV with a specific oligometastasis site (including distant lymph node, distant soft tissue, bone, and viscera), (3) breast cancer was the first primary malignancy, (4) female and no more than 80 years of age, (5) survived for more than 1 month, and (6) diagnosed with breast cancer by histological methods. In addition, patients with bilateral breast cancer or unclear T stage, N stage, M stage, metastatic site, surgical mode, and molecular subtype in the database were excluded. All clinicopathologic information of the patients was registered at the initial diagnosis of breast cancer.

Demographic and clinicopathologic characteristics extracted from SEER were survival status, follow-up time, cause of death (cancer-specific event or not), age at diagnosis, race, marital status, histological type, Scarff-Bloom-Richardson grading system (SBR grade), T stage, N stage, molecular subtype, metastatic site, and therapeutic experience.

In order to construct nomogram, age was transformed into a categorical variable. According to the TNM stage and metastatic site, we classified patients into 3 metastatic stages: (1) involvement of the distant lymph node (including cervical nodes, contralateral axillary, contralateral supraclavicular, and contralateral internal mammary nodes) in the absence of another metastatic site, (2) involvement of distant oligometastasis, (3) and patients in TnN3cM0 stage. The SEER database details the metastatic sites, including soft tissue, bone, and viscera. Distant oligometastasis meant that metastasis had been confirmed at only one site.

There was no personal identifying data appearing in our research. It was not necessary to apply for Institutional Review Board approval or get patient informed consent. Our study protocol was in agreement with the provisions of the Helsinki Declaration as revised in 2013.

2.2. Statistical Analyses. Overall survival (OS) duration was defined as the period from initial diagnosis of breast cancer to all-cause death. Breast cancer-specific survival (BCSS) duration referred to the period from initial diagnosis to cancer-specific death, while deaths from other causes were called competitive events.

A total of 9539 patients were enrolled in this study. Clinicopathological characteristics were compared using the chi-square test. Kaplan-Meier (KM) method and log-rank test were used to compare OS prognosis for patients at different stages. Cox univariate analysis was used to determine significant factors. Cox proportional hazards regression analysis with a forward stepwise procedure was used as a multivariate adjusted model to identify significant prognostic factors and evaluate the hazard ratios with 95% confidence intervals (95% CI). We also carried out Fine-Gray test to compare BCSS prognosis for patients at different stages [27, 28]. Propensity score matching (PSM) was adopted to modulate confounding factors between different populations. We performed logistic regression to evaluate variables associated with OS. Patients were matched on the basis of evaluated propensity using 1 : 1 matching via nearest method without replacement. A caliper of 0.05 was adopted.

Subsequently, patients were randomly allocated into a training and validation cohort at 6:4 ratio. In the training cohort, we utilized KM method and log-rank test to select significant variables. Then, the selected variables were entered into Cox multivariable survival analysis so as to obtain independent prognostic factors for OS prognosis. Based on these factors, a nomogram was developed to predict 1-, 3-, and 5-year OS of SDLNM patients. We
performed internal and external validation in the training and validation cohort. Harrell’s C statistic concordance index (C-index) and receiver operating characteristic (ROC) curves were used to evaluate discrimination of nomogram. Generally, the C-index and area under the ROC curve (AUC) range from 0.5 to 1.0, with 1.0 implying perfect coincidence and 0.5 implying complete randomness. Additionally, calibration plots for 1-, 3-, and 5-year survival were performed to estimate the accuracy of the model. High consistency between a predicted line and a 45-degree line indicates the accuracy of the model. Bootstrapping with 1,000 reiterations was adopted in these analyses. Additionally, independent prognostic factors for BCSS were screened by Fine-Gray univariate and multivariate analyses.

In univariate analysis, a two-sided p value < 0.10 was considered statistically significant, whereas a p value < 0.05 was statistically significant in other conditions. Statistical analyses were performed using SPSS (version 23.0) and R (version 3.6.3).

3. Results

3.1. Baseline Characteristics of the Included Patients. 9539 patients with breast cancer from 2010 to 2016 were enrolled in our study (Figure 1). The median age was 58 (IQR 49-66) years old, and the median follow-up was 33 (IQR 16-45) months. The number of breast cancer patients with stage TnN3cM0, SDLNM, and other oligometastasis was 497, 692, and 8350, respectively. Patients with TNBC subtype had the highest mortality, while patients with other 3 subtypes had adjacent mortality, among which luminal B was correlated with the lowest mortality. All-cause survival probability in 1 year, 3 years, and 5 years for SDLNM patients was 86.5%, 59.9%, and 48.6%, respectively, while that for patients in stage TnN3cM0 was 92%, 65.2%, and 51.5%, respectively. As for patients with other oligometastasis, the OS was 85.8%, 57.8%, and 36.8% in 1 year, 3 years, and 5 years, respectively. Baseline features of the patients are summarized in Table 1.

3.2. Comparison of Diverse Metastatic Stages. KM (Figure 2(a)) and cumulative incidence function (CIF, Figure S1a) curves demonstrated that the OS and BCSS of SDLNM patients were similar to that of patients in stage TnN3cM0, SDLNM, and other oligometastasis was 497, 692, and 8350, respectively. Patients with TNBC subtype had the highest mortality, while patients with other 3 subtypes had adjacent mortality, among which luminal B was correlated with the lowest mortality. All-cause survival probability in 1 year, 3 years, and 5 years for SDLNM patients was 86.5%, 59.9%, and 48.6%, respectively, while that for patients in stage TnN3cM0 was 92%, 65.2%, and 51.5%, respectively. As for patients with other oligometastasis, the OS was 85.8%, 57.8%, and 36.8% in 1 year, 3 years, and 5 years, respectively. Baseline features of the patients are summarized in Table 1.

Figure 1: Flowchart of patient selection, (a) for TnN3cM0 stage, (b) for metastatic breast cancer with oligometastasis. SDLNM: synchronous isolated distant lymph node metastasis.
prognosis compared with patients in other 2 groups, whereas patients with SDLNM had longer survival compared with patients with other oligometastasis (Figure 2(e) and Figure S1e). Cox univariate analysis verified that age, marriage, histology, SBR grade, T stage, metastatic type, subtype, surgery, chemotherapy, and radiotherapy were significant factors for OS. After adjusting for other prognostic parameters via using a Cox stepwise regression model, involvement of SDLNM was associated with similar OS and BCSS prognosis compared with patients in the TnN3cM0 stage (OS: $p = 0.778$; BCSS: $p = 0.670$) and had a greater survival advantage than other MBC patients (OS: hazard ratio, 0.767, 95% CI, 0.672-0.875, $p < 0.001$; BCSS: hazard ratio, 0.755, 95% CI, 0.652-0.874, $p < 0.001$).

### 3.3. Propensiy Score Matching Results.

Since there were imbalance characteristics between diverse metastatic stages, we performed PSM to obtain 2 matched cohorts that could

**Table 1: Demographic and clinicopathologic features of all included patients.**

| Characteristics          | TnN3cM0 (%) | SDLNM (%) | Other oligometastasis (%) | $p$ value |
|--------------------------|-------------|-----------|---------------------------|-----------|
| Age                      |             |           |                           |           |
| $\leq 50\ y$             | 186 (37.4)  | 218 (31.5) | 2371 (28.4)               | $<0.001$  |
| 51-65 y                  | 205 (41.2)  | 302 (43.6) | 3631 (43.5)               |           |
| 66-80 y                  | 106 (21.3)  | 172 (24.9) | 2348 (28.1)               |           |
| Race                     |             |           |                           | $<0.001$  |
| Caucasian                | 351 (70.6)  | 481 (69.5) | 6364 (76.2)               |           |
| Black/AI                 | 108 (21.7)  | 135 (19.5) | 1371 (16.4)               |           |
| Asian                    | 38 (7.6)    | 76 (11.0)  | 615 (7.4)                 |           |
| Marriage                 |             |           |                           | 0.506     |
| Married                  | 256 (51.5)  | 343 (49.6) | 4082 (48.9)               |           |
| Single and unknown       | 241 (48.5)  | 349 (50.4) | 4268 (51.1)               |           |
| Histology                |             |           |                           | $<0.001$  |
| IDC                      | 402 (80.9)  | 556 (80.3) | 6056 (72.5)               |           |
| Non-IDC                  | 95 (19.1)   | 136 (19.7) | 2294 (27.5)               |           |
| SBR grade                |             |           |                           | $<0.001$  |
| Grade 3                  | 255 (51.3)  | 335 (48.4) | 2462 (29.5)               |           |
| Grade 1-2                | 126 (25.4)  | 184 (26.6) | 3651 (43.7)               |           |
| Unknown                  | 116 (23.3)  | 173 (25.0) | 2237 (26.8)               |           |
| T stage                  |             |           |                           | $<0.001$  |
| T0-1                     | 73 (14.7)   | 102 (14.7) | 1247 (14.9)               |           |
| T2                       | 163 (32.8)  | 207 (29.9) | 3266 (39.1)               |           |
| T3                       | 93 (18.7)   | 107 (15.5) | 1607 (19.2)               |           |
| T4                       | 168 (33.8)  | 276 (39.9) | 2230 (26.7)               |           |
| Subtype                  |             |           |                           | $<0.001$  |
| Luminal A                | 174 (35.0)  | 288 (41.6) | 5531 (66.2)               |           |
| Luminal B                | 113 (22.7)  | 127 (18.4) | 1368 (16.4)               |           |
| Her2+ HR-                | 82 (16.5)   | 99 (14.3)  | 564 (6.8)                 |           |
| TNBC                     | 128 (25.8)  | 178 (25.7) | 887 (10.6)                |           |
| Surgery                  |             |           |                           | $<0.001$  |
| None                     | 95 (19.1)   | 271 (39.2) | 4857 (58.2)               |           |
| Lumpectomy               | 87 (17.5)   | 101 (14.6) | 1057 (12.7)               |           |
| Mastectomy               | 315 (63.4)  | 320 (46.2) | 2436 (29.2)               |           |
| Radiotherapy             |             |           |                           | $<0.001$  |
| Yes                      | 293 (59.0)  | 247 (35.7) | 2133 (25.5)               |           |
| No                       | 204 (41.0)  | 445 (64.3) | 6217 (74.5)               |           |
| Chemotherapy             |             |           |                           | $<0.001$  |
| Yes                      | 463 (93.2)  | 578 (83.5) | 5013 (60.0)               |           |
| No                       | 34 (6.8)    | 114 (16.5) | 3337 (40.0)               |           |

SDLNM: synchronous isolated distant lymph node metastasis; Her2: human epidermal growth factor receptor type 2; AI: American Indian; HR: hormone receptor; IDC: infiltrating duct carcinoma; SBR grade: Scarff-Bloom-Richardson grading system; TNBC: triple-negative breast cancer.
be used to further verify the large survival difference. There were 928 patients in matched cohort 1 (464 SDLNM patients and 464 stage TnN3cM0 patients) and 1384 patients in matched cohort 2 (692 SDLNM patients and 692 other oligometastatic patients). The baseline features of these two cohorts are illustrated in Table S1 and Table S2. In matched cohort 1, no significant difference was found between SDLNM patients and stage TnN3cM0 patients. Therefore, stage TnN3cM0 and SDLNM breast cancer patients still had similar prognosis (Figure 3(a) and Figure S2a) after PSM. In matched cohort 2, SDLNM patients had longer OS and BCSS than patients with other oligometastasis (Figure 3(b) and Figure S2b). The PSM results further verified that SDLNM patients had survival identical to TnN3cM0 and were different from stage IV.

3.4. Descriptive Analysis of SDLNM Patients. Among the 692 patients with SDLNM, luminal A, luminal B, Her2 + HR-, and TNBC subtypes accounted for 41.62% (288/692), 18.35% (127/692), 14.31% (99/692), and 25.72% (178/692), respectively. TNBC was associated with the highest mortality (57.3%). Of note, SDLNM was associated with strong tumor
aggressiveness. The proportion of SDLNM patients in stage T4, SBR grade 3, and stage N3 was 39.88% (276/692), 48.41% (335/692), and 40.75% (282/692), respectively. There were 628 (90.75%) patients who had positive ipsilateral nodes. As for curative therapy, 63.84% (421/692) patients underwent local surgery, among which 320 (46.24%) patients received mastectomy. 5-year OS for patients without surgery, with lumpectomy or with mastectomy was 35.7%, 53.9%, and 55.3%, respectively. Additionally, 578 (83.53%) and 247 (35.69%) patients suffered from chemotherapy and radiotherapy, respectively. After adjusting for other prognostic factors, mastectomy clearly improved OS prognosis of patients (hazard ratio, 0.668; 95% CI, 0.487-0.917, \( p = 0.012 \)). However, lumpectomy did not bring survival prognosis benefit (\( p = 0.475 \)). Furthermore, patients who did not receive radiotherapy were prone to have poor prognosis (hazard ratio, 1.745; 95% CI, 1.249-2.439, \( p = 0.001 \)). Of importance, chemotherapy did not seem to have significant effect on OS for SDLNM patients. Figure 4 shows the KM curves of patients receiving surgery and radiotherapy.

As mentioned earlier, the prognosis of SDLNM patients is quite different from other MBC patients. To precisely evaluate the prognosis for this patient population and assist clinical decision making, we aimed to develop predictive models by first randomly placing 416 and 276 patients into a training and validation cohort, respectively. The median follow-up duration in the training and validation cohorts was 32.5 (IQR 15.25-46) months and 33 (IQR 16.25-47.75) months, respectively. There were 152 (36.5%) death events in the training cohort, of which 137 (32.93%) were caused by cancer. Similarly, in the validation cohort, 97 (35.1%) and 92 (33.3%) patients suffered from all-cause and cancer-specific death, respectively. The baseline characteristics of SDLNM patients are shown in Table 2.

3.5. Predictive Model for SDLNM Patient Prognosis. Univariate analysis in the training cohort showed marital status, race, SBR grade, T stage, molecular subtype, surgery, and radiotherapy were associated with OS prognosis for breast cancer patients with SDLNM. Cox multivariate analysis showed that SBR grade, T stage, molecular subtype, surgery,
Table 2: Baseline characteristics of breast cancer patients with SDLNM.

| Characteristic     | Training cohort (n = 416) | Validation cohort (n = 276) | p value |
|--------------------|---------------------------|----------------------------|---------|
| Age (%)            |                           |                            |         |
| ≤50 y              | 136 (32.7)                | 82 (29.7)                  | 0.570   |
| 51-65 y            | 175 (42.1)                | 127 (46.0)                 |         |
| 66-80 y            | 105 (25.2)                | 67 (24.3)                  |         |
| Race (%)           |                           |                            |         |
| White              | 294 (70.7)                | 187 (67.8)                 | 0.716   |
| Black/AI           | 78 (18.8)                 | 57 (20.7)                  |         |
| Asian              | 44 (10.6)                 | 32 (11.6)                  |         |
| Marriage (%)       |                           |                            |         |
| Married            | 210 (50.5)                | 133 (48.2)                 | 0.555   |
| Single and unknown | 206 (49.5)                | 143 (51.8)                 |         |
| Histology (%)      |                           |                            |         |
| IDC                | 332 (79.8)                | 224 (81.2)                 | 0.661   |
| Non-IDC            | 84 (20.2)                 | 52 (18.8)                  |         |
| SBR grade (%)      |                           |                            |         |
| Grade 3            | 206 (49.5)                | 129 (46.7)                 | 0.455   |
| Grade 1-2          | 113 (27.2)                | 71 (25.7)                  |         |
| Unknown            | 97 (23.3)                 | 76 (27.5)                  |         |
| T stage (%)        |                           |                            |         |
| T0-1               | 66 (15.9)                 | 36 (13.0)                  | 0.477   |
| T2                 | 116 (27.9)                | 91 (33.0)                  |         |
| T3                 | 65 (15.6)                 | 42 (15.2)                  |         |
| T4                 | 169 (40.6)                | 107 (38.8)                 |         |
| N stage (%)        |                           |                            | 0.124   |
| N0                 | 47 (11.3)                 | 17 (6.2)                   |         |
| N1                 | 158 (38.0)                | 108 (39.1)                 |         |
| N2                 | 44 (10.6)                 | 36 (13.0)                  |         |
| N3                 | 167 (40.1)                | 115 (41.7)                 |         |
| Subtype (%)        |                           |                            | 0.367   |
| Luminal A          | 167 (40.1)                | 121 (43.8)                 |         |
| Luminal B          | 74 (17.8)                 | 53 (19.2)                  |         |
| Her2 + HR-TNBC     | 58 (13.9)                 | 41 (14.9)                  |         |
| Surgery (%)        |                           |                            | 0.366   |
| None               | 154 (37.0)                | 117 (42.4)                 |         |
| Lumpectomy         | 63 (15.1)                 | 38 (13.8)                  |         |
| Mastectomy         | 199 (47.8)                | 121 (43.8)                 |         |
| Radiotherapy (%)   |                           |                            | 0.937   |
| Yes                | 148 (35.6)                | 99 (35.9)                  |         |
| No                 | 268 (64.4)                | 177 (64.1)                 |         |
| Chemotherapy (%)   |                           |                            | 0.247   |
| Yes                | 353 (84.9)                | 225 (81.5)                 |         |
| No                 | 63 (15.1)                 | 51 (18.5)                  |         |
| Status (%)         |                           |                            | 0.708   |
| Alive              | 264 (63.5)                | 179 (64.9)                 |         |
| Dead               | 152 (36.5)                | 97 (35.1)                  |         |

AI: American Indian; Her2: human epidermal growth factor receptor type 2; HR: hormone receptor; IDC: infiltrating duct carcinoma; SBR grade: Scarff-Bloom-Richardson grading system; SDLNM: synchronous isolated distant lymph node metastasis; TNBC: triple-negative breast cancer.
and radiotherapy were independent prognostic parameters. The results of univariate and multivariate analyses are shown in Table 3. It is worth noting that N stage and chemotherapy were not significant predictors for OS.

The abovementioned significant variables were integrated to establish a prediction model. A nomogram for predicting the 1-, 3-, and 5-year OS was established (Figure 5(a)). Each predictor utilized to develop the nomogram was assigned a score. By adding all scores that relied on patient clinicopathological features to obtain a total score, a straight line from the "Points" to "OS probability" axis was drawn to estimate the prognosis of patients. Of importance, mastectomy brought significant OS advantages for SDLNM patients.

The C-index of the nomogram for predicting the 1-, 3-, and 5-year OS prognosis was 0.731 (95% CI 0.692-0.770) and 0.722 (95% CI 0.671-0.773) in the training and validation cohort, respectively. ROC curves are plotted in Figure S3. All C-indexes and AUCs were greater than 0.7, which implies good predictive discrimination. Calibration curves indicated the precise predictive efficiency of the models both in training and validation cohort (Figure 6).

Fine-Gray univariate and multivariate analysis revealed that SBR grade, T stage, molecular subtype, and radiotherapy were significantly associated with BCSS (Table 3).

### Table 3: Univariate and multivariate analyses for OS and BCSS of breast cancer patients with SDLNM.

| Variables | OS (Univariate) | Multivariate | BCSS (Univariate) | Multivariate |
|-----------|-----------------|--------------|-------------------|--------------|
| Age       | 0.31            |              | 0.836             |              |
| Marriage  | 0.046           | 1.27 (0.91, 1.78) | 0.156 | 0.132 |
| Race      | 0.025           |              | 0.023             |              |
| White     | Reference       |              | Reference         |              |
| Black/AI  | 1.24 (0.84, 1.84) | 0.283       | 1.42 (0.93, 2.17) | 0.100 |
| Asian     | 0.59 (0.28, 1.23) | 0.160       | 0.37 (0.32, 1.44) | 0.310 |
| Histology | 0.24            |              |                  | 0.557 |
| SBR grade | <0.001          |              | <0.001            |              |
| Grade 3   | Reference       |              | Reference         |              |
| Grade 1-2 | 0.58 (0.37, 0.91) | 0.016*      | 0.52 (0.31, 0.86) | 0.011* |
| Unknown   | 0.69 (0.45, 1.05) | 0.082       | 0.72 (0.45, 1.16) | 0.180 |
| T stage   | 0.013           |              | 0.094             |              |
| T4        | Reference       |              | Reference         |              |
| T3        | 0.65 (0.39, 1.10) | 0.106       | 0.64 (0.38, 1.08) | 0.097 |
| T2        | 0.56 (0.37, 0.84) | 0.005*      | 0.62 (0.38, 0.98) | 0.043* |
| T0-1      | 0.41 (0.24, 0.69) | <0.001*     | 0.53 (0.30, 0.95) | 0.032* |
| N stage   | 0.118           |              | 0.098             |              |
| N3        | Reference       |              | Reference         |              |
| N2        | 0.64 (0.38, 1.08) | 0.057       |                  |              |
| N1        | 0.62 (0.38, 0.99) | 0.580       |                  |              |
| N0        | 0.53 (0.30, 0.95) | 0.530       |                  |              |
| Subtype   | <0.001          |              | <0.001            |              |
| Luminal A | Reference       |              | Reference         |              |
| Luminal B | 0.49 (0.29, 0.87) | 0.014*      | 0.43 (0.23, 0.80) | 0.007* |
| Her2 + HR-| 0.56 (0.30, 1.04) | 0.064       | 0.49 (0.25, 0.94) | 0.032* |
| TNBC      | 2.21 (1.49, 3.28) | <0.001*     | 2.07 (1.31, 3.27) | 0.002* |
| Surgery   | 0.001           |              | 0.004             |              |
| None      | Reference       |              | Reference         |              |
| Lumpectomy| 0.85 (0.49, 1.47) | 0.555       | 1.01 (0.58, 1.77) | 0.960 |
| Mastectomy| 0.63 (0.41, 0.95) | 0.026*      | 0.79 (0.50, 1.25) | 0.310 |
| Radiotherapy | <0.001          | 1.61 (1.07, 2.44) | 0.024* | <0.001 |
| Chemotherapy | 0.171           |              | 1.83 (1.19, 2.84) | 0.006* |

BCSS: breast cancer-specific survival; CI: confidence intervals; Her2: human epidermal growth factor receptor type 2; HR: hormone receptor; OS: overall survival; SBR grade: Scarff-Bloom-Richardson grading system; SDLNM: synchronous isolated distant lymph node metastasis; TNBC: triple-negative breast cancer.
between SDLNM and TnN3cM0 stage, we explored whether chemotherapy provided a survival advantage. There were 320 SDLNM patients who underwent mastectomy, and 101 patients received lumpectomy. KM analysis indicated that chemotherapy and radiotherapy increased OS of patients who underwent mastectomy (Figure 7), but not patients who received lumpectomy. After adjusting for other factors, patients who received mastectomy still benefited from chemotherapy and postoperative radiotherapy (chemotherapy: hazard ratio, 1.973, 95% CI, 1.033-3.769, \( p = 0.040 \); postoperative radiotherapy: hazard ratio, 1.669, 95% CI, 1.102-2.529, \( p = 0.016 \)).

### Discussion

Breast cancer with SDLNM is an infrequent disease. Cervical lymph node metastasis (CLNM) occurs in only 1% of breast cancers, whereas the incidence of contralateral axillary node metastasis (CAM) is 1.9-6.0% \( ^{6,19} \). Perre et al. \[29\] applied regional lymphoscintigraphy to 23 patients before and after breast surgery and found that the lymphatic drainages of 7 postoperative patients drained to the contralateral lymphatic network, among which 6 drained to the axilla and 1 was diverted to the internal mammary nodes, implying that the incidence of contralateral internal mammary node metastasis may be much lower than that of CAM.

Prospective and retrospective studies evaluating the treatment and prognosis of breast cancer patients with DLNM are difficult to perform due to the extremely low incidence. Most relevant literature involves case reports \[10, 11, 18, 21, 22, 30–32\]. Because of the lack of large sample size in studies, staging and prognosis of DLNM patients in the absence of other distant metastasis still remain controversial. In terms of anatomy, tumor cells migrate to distant lymph nodes via lymphatic network rather than blood circulation, so DLNM should not be categorized as stage M1 \[9\]. Several reports indicate that the prognosis of breast cancer patients with cervical and contralateral node metastasis is similar to that of patients at the N3c stage \[9, 11, 15–19\]. Moossdorff et al. \[17\] summarized 24 previous studies and proposed that the survival of patients with contralateral lymph node metastasis is not comparable to patients with other distant metastatic diseases (the average OS after 50.3-month follow-up was 82.6%). Recently, an Italian study analyzed 47 patients with CAM and suggested that the estimated 5-year OS and progression-free survival after multidisciplinary treatment are 72% (95% CI 54-83) and 61% (95% CI 44-74), respectively \[16\]. In addition, another retrospective study KROG 18-02 reviewed 78 patients with cervical lymph node metastasis from 7 institutions and found that the 5-year OS, disease-free survival, locoregional relapse-free survival, and distant metastasis-free survival after treatment were 68.6%, 46.7%, 68.4%, and 57.0%, respectively, and quite different from the 5-year OS for MBC of 26-49% \[15\]. However, Guru et al. \[23\] reviewed 23 breast cancer patients with metachronous CAM and concluded that the prognosis of CAM patients was similar to that of MBC patients with oligometastasis. Our research substantiates that the OS and BCSS prognoses of SDLNM breast cancer patients are similar to those for N3c stage patients and are superior to those of other oligometastatic MBC patients, especially for long-term prognosis. For short-term prognosis, SDLNM has few survival advantages compared with the other 2 stages. It is worth mentioning that only approximately half the population in our study received surgery and radiation, and fewer received combination therapy, whereas all participants in the above studies received comprehensive treatment regimens.

Generally, lymph flows along interlobular vessels of the breast into the subareolar plexus and then follows the
Figure 6: Internal and external calibration curves for nomogram predicting the 1-, 3-, and 5-year OS of breast cancer SDLNM patients. (a)–(c) Training cohort. (d)–(f) Validation cohort. OS: overall survival; SDLNM: synchronous isolated distant lymph node metastasis.

Figure 7: KM curves for chemotherapy (a) and postoperative radiotherapy (b) for SDLNM patients. SDLNM: synchronous isolated distant lymph node metastasis.
mammary veins to the axilla (75%). Lymph from the medial breast can also flow into the parasternal lymph nodes [33]. DLNM may be caused by the diversion and retrogradation of lymphatic drainage following the destruction of the ipsilateral lymphatic network [7, 9–11]. Associated risk factors include large mammary neoplasm, previous mammary or axillary surgery and radiation, and large tumor burdens in the ipsilateral axilla [7, 9, 11]. Allweis et al. [31] retrospectively analyzed 21 cases of CAM, among which 10 cases were synchronous and 11 were metachronous. For patients with internal breast involvement, a retrosternal route crossing to the contralateral was possible. Morcos et al. [12] retrospectively analyzed 21 cases of CAM, among which 10 cases were synchronous and 11 were metachronous. The histopathological features of CAM patients were significantly worse, such as lymphatic vascular invasion (81%), high histological grade (81% grade 3), large primary breast neoplasms (95% cT3/cT4), estrogen receptor negativity (52%), and overexpression of Her2 (42%). Our study is in agreement with this. Among 692 participants, patients with invasive characteristics including large tumors, high SBR grade, ipsilateral lymph node metastasis, and TNBC subtype accounted for a high proportion.

Clinicians generally adopt comprehensive treatment for DLNM patients and to obtain acceptable curative outcomes [9–11, 16–18, 20–22, 32]. Some clinicians also implement palliative treatment [19, 30]. Several retrospective studies suggest that surgery and systemic therapy enhance the prognosis of patients with DLNM [9, 15, 16]. However, there are some differences between operational methods and combined schemes. Kim et al. [15] considered that cervical lymph node metastasis patients could benefit from systemic chemotherapy and locoregional therapy for the ipsilateral breast, but neck dissection and radiotherapy does not improve locoregional relapse-free survival and disease-free survival. Magnoni et al. [16] found that contralateral axillary lymph node dissection provide a prognostic advantage for CAM patients. However, chemotherapy and postaxillary lymph node dissection radiotherapy did not appear to improve OS (p = 0.13 and p = 0.65) or disease-free survival (p = 0.25 and p = 0.5). In addition, a Chinese study reviewed 25 CAM cases and proposed that the combination of surgery, systemic chemotherapy, radiotherapy, and anthrhorone therapy is more effective in controlling disease compared with mastectomy and axillary lymph node dissection alone [20]. Oppositely, Wong et al. [19] performed a retrospective analysis of 15 synchronous CAM patients, and the comparison showed no significant difference in 5-year cancer-specific survival between the palliative and operative groups (68.6% vs. 80.0%, p = 0.79). Our research study suggests that mastectomy with chemotherapy and postoperative radiotherapy significantly improves OS for breast cancer patients with SDLNM, while lumpectomy, chemotherapy, or postlumpectomy chemotherapy does not increase OS. In brief, a comprehensive curative program on SDLNM breast cancer patients, just like that performed for locally advanced breast cancer patients, remarkably prolongs OS.

This is the first large-sample study that retrospectively analyses the prognosis and treatment of breast cancer patients with SDLNM, with the purpose of providing a reference for staging and curative planning. There are some limitations in our research. First, due to the limited treatment information from the SEER database, we were unable to analyze the roles of lymphadenectomy of metastatic lymph nodes, which will require further studies to explore and improve our models. Second, the prognosis of patients with SDLNM was disparate among diverse subtypes. Therefore, it is important to assess the prognosis and optimal treatment for SDLNM patients according to molecular subtypes in the future. Finally, our study only includes patients from the SEER, so a subsequent study from other countries will be needed for verification.

5. Conclusions

Breast cancer with SDLNM might be classified as locally advanced disease, but not metastatic disease. Comprehensive therapy combined with mastectomy, postchemotherapy, and postoperative radiotherapy brings significant survival advantage. We developed predictive models to evaluate the 1-, 3-, and 5-year OS for SDLNM patients. This optional tool may help clinicians formulate therapy and follow-up arrangement based on individual conditions and provide a reference for the design of subsequent prospective trials.

Data Availability

The data of this study are from SEER database.

Ethical Approval

The research did not involve animal experiments and human specimens, no ethics-related issues.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

(I) Liming Chen contributed to the conception and design. (II) Hong Lin contributed to the provision of study materials or patients. (III) Hong Lin and Jianxiong Lin contributed to the collection and assembly of data. (IV) All authors contributed to the data analysis, interpretation, and manuscript writing. All authors contributed to the final approval of manuscript. Hong Lin and Jianxiong Lin contributed equally to this work.

Acknowledgments

The authors would like to thank SEER for open access to the database.

Supplementary Materials

Table S1: characteristics of BC patients with SLDNM or stage TnN3cM0 before and after PSM. Table S2: characteristics of BC patients with SLDNM or other oligometastasis before and after PSM. Figure S1: cumulative mortality curves
for patients with diverse stages in different populations (a) for all included patients; (b) for luminal A subtype; (c) for luminal B subtype; (d) for Her2+ HR- subtype; (e) for TNBC subtype). SDLNM: synchronous isolated distant lymph node metastasis; Her2: human epidermal growth factor receptor type 2; HR: hormone receptor; TNBC: triple-negative breast cancer; BCSM: breast cancer-specific mortality. Figure S2: cumulative mortality curves for PSM cohorts. (a) For PSM cohort 1 (SDLNM vs. IIIc stage); (b) for PSM cohort 2 (SDLNM vs. other oligometastasis). PSM: propensity score matching; SDLNM: synchronous isolated distant lymph node metastasis; BCSM: breast cancer-specific mortality. Figure S3: receiver operating characteristic (ROC) curves for nomogram predicting 1-, 3-, and 5-year OS prediction of SDLNM patients; (a)–(c) for training cohort; (d)–(f) for validation cohort. AUC: area under roc curve; OS: overall survival; SDLNM: synchronous isolated distant lymph node metastasis. (Supplementary Materials)

References

[1] Global Burden of Disease Cancer Collaboration, C. Fitzmaurice, D. Abate et al., "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study," JAMA Oncology, vol. 5, no. 12, pp. 1749–1768, 2019.

[2] C. E. DeSantis, S. A. Fedewa, A. Goding Sauer, J. L. Kramer, R. A. Smith, and A. Jemal, "Breast cancer statistics, 2015: convergence of incidence rates between black and white women," CA: a Cancer Journal for Clinicians, vol. 66, no. 1, pp. 31–42, 2016.

[3] O. Pagani, E. Senkus, W. Wood et al., "International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?", Journal of the National Cancer Institute, vol. 102, no. 7, pp. 456–463, 2010.

[4] M. B. Amin, F. L. Greene, S. B. Edge et al., "The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging," CA: a Cancer Journal for Clinicians, vol. 67, no. 2, pp. 93–99, 2017.

[5] W. J. Gradishar, B. O. Anderson, R. Balassanian et al., "Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology," Journal of the National Comprehensive Cancer Network: JNCCN, vol. 16, no. 3, pp. 310–320, 2018.

[6] L. Jansen, M. H. Doting, E. J. Rutgers, J. de Vries, R. A. Olmos, and O. E. Nieweg, "Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer," The British Journal of Surgery, vol. 87, no. 7, pp. 920–925, 2002.

[7] E. Barranger, F. Montravers, K. Kerrou et al., "Contralateral axillary sentinel lymph node drainage in breast cancer: a case report," Journal of Surgical Oncology, vol. 86, no. 3, pp. 167–169, 2004.

[8] A. N. Pedersen, S. Møller, K. D. Steffensen et al., "Supraclavicular recurrence after early breast cancer: a curable condition?," Breast Cancer Research and Treatment, vol. 125, no. 3, pp. 815–822, 2011.

[9] R. Chikheidez, M. A. G. Sanders, B. Haley, A. M. Leitch, and S. Sahoo, "Isolated contralateral axillary lymph node involvement in breast cancer represents a locally advanced disease not distant metastases," Clinical Breast Cancer, vol. 18, no. 4, pp. 298–304, 2018.

[10] G. Uçmak Vural, I. Şahiner, S. Demirtaş, H. Efe-tracking, and B. B. Demirel, "Sentinel lymph node detection in contralateral axilla at initial presentation of a breast cancer patient: case report," Molecules Imaging and Radiopharmaceuticals, vol. 24, no. 2, pp. 90–93, 2015.

[11] J. S. Vicente, M. L. Dominguez Grande, C. D. Barquero et al., "Bilateral axillary and internal mammary drainage in breast cancer without prior surgery during sentinel node mapping," Indian journal of nuclear medicine: IJNM: the official journal of the Society of Nuclear Medicine, India, vol. 26, no. 4, article 106716, pp. 205–207, 2011.

[12] B. Morcos, I. Jaradat, and M. El-Ghanem, "Characteristics of and therapeutic options for contralateral axillary lymph node metastasis in breast cancer," European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 37, no. 5, pp. 418–421, 2011.

[13] R. A. Brito, V. Valero, A. U. Buzdar et al., "Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas M.D. Anderson Cancer Center experience," Journal of clinical oncology: official journal of the American society of Clinical Oncology, vol. 19, no. 3, pp. 628–633, 2001.

[14] S. E. Singleterry, C. Allred, P. Ashley et al., "Revision of the American Joint Committee on Cancer staging system for breast cancer," Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 20, no. 17, pp. 3628–3636, 2002.

[15] J. S. Kim, K. Kim, K. H. Shin et al., "Cervical lymph node involvement above the supraclavicular fossa in breast cancer: comparison with stage IIIC (KROG 18-02)," Journal of Breast Cancer, vol. 23, no. 2, pp. 194–204, 2020.

[16] F. Magnoni, M. Colleoni, D. Mattar et al., "Contralateral axillary lymph node metastases from breast carcinoma: is it time to review TNM cancer staging?," Annals of Surgical Oncology, vol. 27, no. 11, pp. 4488–4499, 2020.

[17] M. Moosse-dorf, G. Vugs, A. J. Maasakant-Braat et al., "Contralateral lymph node recurrence in breast cancer: regional event rather than distant metastatic disease. A systematic review of the literature," European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 41, no. 9, pp. 1128–1135, 2015.

[18] R. Qin, Q. Zhang, J. Weng et al., "Treatment and prognosis for retrograde cervical lymph node metastases in breast cancer," Contemporary oncology (Poznan, Poland), vol. 2, no. 2, article 45307, pp. 154–156, 2015.

[19] R. X. Wong, G. Kusumawidjaja, and V. Tan, "Solitary contralateral axillary metastasis in breast cancer: is it a true distant spread?," The Breast Journal, vol. 26, no. 7, pp. 1493-1494, 2020.

[20] W. Wang, P. Yuan, J. Wang et al., "Management of contralateral axillary lymph node metastasis from breast cancer: a clinical dilemma," Tumori, vol. 100, no. 6, pp. 600–604, 2014.

[21] J. P. Yuan, X. X. Yuan, L. K. Gao, H. Wu, X. X. Yu, and H. L. Yan, "Occult breast cancer with ipsilateral axillary and cervical lymph node metastasis: report of a case," Zhonghua bing li xue za zhi = Chinese journal of pathology, vol. 46, no. 11, pp. 797–798, 2017.
[22] C. Zhou, M. C. Richir, M. W. Leenders, B. L. Langenhorst, H. P. Knol, and W. H. Schreurs, "Contralateral axillary lymph node metastases at the time of primary breast cancer diagnosis: curative or palliative intent?,” *Case reports in surgery*, vol. 2013, Article ID 389013, 3 pages, 2013.

[23] S. D. Guru, C. L. Loprinzi, E. Yan, T. L. Hoskin, and J. W. Jakub, "Contralateral axillary metastases in breast cancer: stage IV disease or a locoregional event?,” *The American Surgeon*, vol. 85, no. 12, pp. 1391–1396, 2019.

[24] V. P. Balachandran, M. Gonen, J. J. Smith, and R. P. DeMatteo, "Nomograms in oncology: more than meets the eye,” *The Lancet Oncology*, vol. 16, no. 4, pp. e173–e180, 2015.

[25] Y. Q. Huang, C. H. Liang, L. He et al., “Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer,” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 34, no. 18, pp. 2157–2164, 2016.

[26] A. Iasonos, D. Schrag, G. V. Raj, and K. S. Panageas, "How to build and interpret a nomogram for cancer prognosis,” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 26, no. 8, pp. 1364–1370, 2008.

[27] J. P. Fine and R. J. Gray, "A proportional hazards model for the subdistribution of a competing risk,” *Journal of the American Statistical Association*, vol. 94, no. 446, pp. 496–509, 1999.

[28] L. Scrucca, A. Santucci, and F. Aversa, "Regression modeling of competing risk using R: an in depth guide for clinicians,” *Bone Marrow Transplantation*, vol. 45, no. 9, pp. 1388–1395, 2010.

[29] C. I. Perre, C. A. Hoefnagel, B. B. Kroon, F. A. Zoetmulder, and E. J. Rutgers, "Altered lymphatic drainage after lymphadenectomy or radiotherapy of the axilla in patients with breast cancer,” *The British Journal of Surgery*, vol. 83, no. 9, p. 1258, 1996.

[30] K. Adachi, K. Sakurai, H. Kubota et al., "Advanced-stage breast cancer discovered by cervical lymphadenopathy in an elderly patient-report of a case,” *Gan to kagaku ryoho Cancer & chemotherapy*, vol. 46, no. 2, pp. 312–314, 2019.

[31] T. M. Allweis, B. Parson, M. Klein et al., "Breast cancer draining to bilateral axillary sentinel lymph nodes,” *Surgery*, vol. 134, no. 3, pp. 506–508, 2003.

[32] R. Valhondo-Rama, C. G. Wakfe-Corieh, E. A. Rodriguez Gallo et al., "Contralateral axillary sentinel lymph node drainage in breast cancer: controversies and management according to the literature. A case report,” *Revista Espanola De Medicina Nuclear E Imagen Molecular*, vol. 38, no. 5, pp. 316–319, 2019.

[33] A. Sood, I. M. Youssef, S. I. Heiba et al., "Alternative lymphatic pathway after previous axillary node dissection in recurrent/primary breast cancer,” *Clinical Nuclear Medicine*, vol. 29, no. 11, pp. 698–702, 2004.